Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

Franco M. Muggia, Claire F. Verschraegen, Leonard Liebes et al.|Journal of Clinical Oncology|2009

Cited by 10